On December 9, 2014, the PTAB issued its Final Written Decision in each of the three separate, but related, Inter Parte Review proceedings, captioned as Amneal Pharmaceuticals, LLC ("Amneal") v. Supernus Pharmaceuticals, Inc. ("Supernus"). The Final Written Decisions, finding each challenged claim not unpatentable on the instituted grounds, represent more than just a win for patentee Supernus—they represent the first successfully defended IPR proceedings of Orange Book listed patents. This article discusses the PTAB IPR proceedings for the challenged patents, specifically the '740 patent.
Previously published in the AIPLA Chemical Practice Chronicles Newsletter
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
